Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension

Inclusion Criteria: * Male or female patients * Secondary pulmonary hypertension * Mean pulmonary artery pressure equal or above 40 mmHg or primary pulmonary hypertension with a pressure equal or above 30 mmHg while resting during appropriate conventional treatment * Written informed consent after having been duly informed about all diagnostic and therapeutic measures involved in the study Exclusion Criteria: * Clinical Instability at baseline * Pulmonary venous obstruction * Global respiratory insufficiency * Obstructive ventilation disorders, Interstitial pulmonary disease * Cerebrovascular events * Myocardial infarction or major cardiac surgery within 3 months prior to baseline * Bleeding disorders or bleeding risk * Severe hepatic insufficiency or renal insufficiency * Malignant diseases * HIV positive * Pregnancy, female patients of child-bearing potential without adequate contraception and nursing mothers * Congenital or acquired valvular defects and myocardial function disorders not related to pulmonary hypertension * Prior pulmonary embolism * Collagenosis * Pulmonary arterial or valvular stenosis